Prasad, V., Haslam, A. & Olivier, T. Updated estimates of eligibility and response: immune checkpoint inhibitors. J. Clin. Oncol. 42, e14613 (2024).
Schachter, J. et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet 390, 1853–1862 (2017).
RodrÍguez, E., Schetters, S. T. T. & van Kooyk, Y. The tumour glyco-code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol. 18, 204–211 (2018).
Rodrigues Mantuano, N., Natoli, M., Zippelius, A. & Läubli, H. Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy. J. Immunother. Cancer 8, e001222 (2020).
Läubli, H. & Borsig, L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front. Immunol. 10, 2120 (2019).
Smith, B. A. H. & Bertozzi, C. R. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. Nat. Rev. Drug Discov. 20, 217–243 (2021).
Natoni, A., Macauley, M. S. & O’Dwyer, M. E. Targeting selectins and their ligands in cancer. Front. Oncol. 6, 93 (2016).
Liu, F.-T. & Rabinovich, G. A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 5, 29–41 (2005).
Mariño, K. V., Cagnoni, A. J., Croci, D. O. & Rabinovich, G. A. Targeting galectin-driven regulatory circuits in cancer and fibrosis. Nat. Rev. Drug Discov. 22, 295–316 (2023).
Bandala-Sanchez, E. et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat. Immunol. 14, 741–748 (2013).
Laubli, H. et al. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer. Proc. Natl Acad. Sci. USA 111, 14211–14216 (2014).
Xiao, H., Woods, E. C., Vukojicic, P. & Bertozzi, C. R. Precision glycocalyx editing as a strategy for cancer immunotherapy. Proc. Natl Acad. Sci. USA 113, 10304–10309 (2016).
Stanczak, M. A. et al. Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells. J. Clin. Invest. 128, 4912–4923 (2018).
Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 25, 656–666 (2019).
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019).
Gray, M. A. et al. Targeted glycan degradation potentiates the anticancer immune response in vivo. Nat. Chem. Biol. 16, 1376–1384 (2020).
Wisnovsky, S. et al. Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7. Proc. Natl Acad. Sci. USA 118, e2015024118 (2021).
Rodriguez, E. et al. Sialic acids in pancreatic cancer cells drive tumour-associated macrophage differentiation via the Siglec receptors Siglec-7 and Siglec-9. Nat. Commun. 12, 1270 (2021).
Haas, Q. et al. Siglec-9 regulates an effector memory CD8+ T-cell subset that congregates in the melanoma tumor microenvironment. Cancer Immunol. Res. 7, 707–718 (2019).
Ibarlucea-Benitez, I., Weitzenfeld, P., Smith, P. & Ravetch, J. V. Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunity. Proc. Natl Acad. Sci. USA 118, e2107424118 (2021).
Haas, Q. et al. Siglec-7 represents a glyco-immune checkpoint for non-exhausted effector memory CD8+ T cells with high functional and metabolic capacities. Front. Immunol. 13, 996746 (2022).
Stanczak, M. A. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Sci. Transl. Med. 14, eabj1270 (2022).
Theruvath, J. et al. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication. Nat. Med. 28, 333–344 (2022).
Daly, J. et al. Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses. Blood Adv. 6, 3352–3366 (2022).
Schmassmann, P. et al. Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma. Sci. Transl. Med. 15, eadf5302 (2023).
Bordoloi, D. et al. Siglec-7 glyco-immune binding mAbs or NK cell engager biologics induce potent antitumor immunity against ovarian cancers. Sci. Adv. 9, eadh4379 (2023).
Szijj, P. A. et al. Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer. Nat. Chem. 15, 1636–1647 (2023).
Egan, H. et al. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment. Cell Rep. 42, 112475 (2023).
Lustig, M. et al. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells. Front. Immunol. 14, 1178817 (2023).
Mei, Y. et al. Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response. Nat. Cancer 4, 1273–1291 (2023).
Yang, Z. et al. Targeted desialylation and cytolysis of tumour cells by fusing a sialidase to a bispecific T-cell engager. Nat. Biomed. Eng. 8, 499–512 (2024).
Wang, Y. et al. Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis. Proc. Natl Acad. Sci. USA 121, e2312929121 (2024).
Wen, R. M. et al. Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer. J. Clin. Invest. 134, e180282 (2024).
O'Neill, A. et al. Stromal cells modulate innate immune cell phenotype and function in colorectal cancer via the sialic acid/Siglec axis. J. Immunother. Cancer 13, e012491 (2025).
Sterner, E., Flanagan, N. & Gildersleeve, J. C. Perspectives on anti-glycan antibodies gleaned from development of a community resource database. ACS Chem. Biol. 11, 1773–1783 (2016).
Smith, B. A. H. et al. MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint. Proc. Natl Acad. Sci. USA 120, e2215376120 (2023).
Büll, C., Heise, T., Adema, G. J. & Boltje, T. J. Sialic acid mimetics to target the sialic acid–Siglec axis. Trends Biochem. Sci. 41, 519–531 (2016).
Pedram, K. et al. Design of a mucin-selective protease for targeted degradation of cancer-associated mucins. Nat. Biotechnol. 42, 597–607 (2024).
Filipovic, A. et al. Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors. J. Immunother. Cancer 9, A512 (2021).
Shum, E., et al. Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors. J. Immunother. Cancer 9, A520–A521 (2021).
Luke, J. J. et al. Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors. Cancer Res. 83, CT034 (2023).
Dimitriou, F. et al. Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an institutional database analysis. Cancers 13, 2931 (2021).
NextCure, Inc. A safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors. ClinicalTrials.gov https://clinicaltrials.gov/study/NCT03665285 (2025).
Perez, E. A. et al. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res. Treat. 194, 1–11 (2022).
Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).
Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12, 832 (2021).
Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160–170 (2010).
Gullo, G., Zuradelli, M., Sclafani, F., Santoro, A. & Crown, J. Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer. Ann. Oncol. 23, 2204–2205 (2012).
Witzel, I. et al. Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer—results from the HER-OS patient registry. BMC Cancer 14, 806 (2014).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Bang, Y.-J. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687–697 (2010).
Rugo, H. S. et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 7, 573–584 (2021).
Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677–681 (1998).
Delaveris, C. S., Chiu, S. H., Riley, N. M. & Bertozzi, C. R. Modulation of immune cell reactivity with cis-binding Siglec agonists. Proc. Natl Acad. Sci. USA 118, e2012408118 (2021).
Bruncsics, B., Errington, W. J. & Sarkar, C. A. MVsim is a toolset for quantifying and designing multivalent interactions. Nat. Commun. 13, 117 (2022).
Errington, W. J., Bruncsics, B. & Sarkar, C. A. Mechanisms of noncanonical binding dynamics in multivalent protein–protein interactions. Proc. Natl Acad. Sci. USA 116, 25659–25667 (2019).
Gasparrini, F. et al. Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling. EMBO J. 35, 258–280 (2016).
Spence, S. et al. Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation. Sci. Transl. Med. 7, 303ra140 (2015).
McCord, K. A. et al. Dissecting the ability of Siglecs to antagonize Fcγ receptors. ACS Cent. Sci. 10, 315–330 (2024).
Mazor, Y. et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 7, 377–389 (2015).
Elliott, J. M. et al. Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2–CH3 hydrophobic interaction. J. Mol. Biol. 426, 1947–1957 (2014).
Angata, T., von Gunten, S., Schnaar, R. L. & Varki, A. I-type lectins. In Essentials of Glycobiology (eds Varki, A. et al.) 475–490 (Cold Spring Harbor Laboratory Press, 2022).
Smith, P., DiLillo, D. J., Bournazos, S., Li, F. & Ravetch, J. V. Mouse model recapitulating human Fcγ receptor structural and functional diversity. Proc. Natl Acad. Sci. USA 109, 6181–6186 (2012).
Sharma, P. & Allison, J. P. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).
Morrissey, M. A., Kern, N. & Vale, R. D. CD47 ligation repositions the inhibitory receptor SIRPA to suppress integrin activation and phagocytosis. Immunity 53, 290–302.e6 (2020).
Miller, W. D. et al. CD47 inhibits phagocytosis through Vav dephosphorylation. J. Cell Biol. 224, e202502206 (2025).
Upton, R. et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc. Natl Acad. Sci. USA 118, e2026849118 (2021).
Shitara, K. et al. Final analysis of the randomized phase 2 part of the ASPEN-06 study: a phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC). J. Clin. Oncol. 43, 332 (2025).
Daver, N. et al. The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy. Blood 146, 601–611 (2025).
Wilcke, M. et al. Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-Golgi network. J. Cell Biol. 151, 1207–1220 (2000).
Fairn, G. D. & Grinstein, S. How nascent phagosomes mature to become phagolysosomes. Trends Immunol. 33, 397–405 (2012).
Jiang, C. et al. Inactivation of Rab11a GTPase in macrophages facilitates phagocytosis of apoptotic neutrophils. J. Immunol. 198, 1660–1672 (2017).
Krug, K. et al. A curated resource for phosphosite-specific signature analysis. Mol. Cell. Proteom. 18, 576–593 (2019).
Scatizzi, J. C. et al. The CDK domain of p21 is a suppressor of IL-1β-mediated inflammation in activated macrophages: innate immunity. Eur. J. Immunol. 39, 820–825 (2009).
Lloberas, J. & Celada, A. p21(waf1/CIP1), a CDK inhibitor and a negative feedback system that controls macrophage activation: HIGHLIGHTS. Eur. J. Immunol. 39, 691–694 (2009).
Xu, J. et al. Inhibition of cyclin-dependent kinase 2 signaling prevents liver ischemia and reperfusion injury. Transplantation 103, 724–732 (2019).
Nunes, M. P. et al. Inhibitory effects of Trypanosoma cruzi sialoglycoproteins on CD4+ T cells are associated with increased susceptibility to infection. PLoS ONE 8, e77568 (2013).
Tarantino, P. et al. HER2-low breast cancer: pathological and clinical landscape. J. Clin. Orthod. 38, 1951–1962 (2020).
Mittendorf, E. A. et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin. Cancer Res. 15, 7381–7388 (2009).
Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189–2201 (2017).
Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018).
Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
Chao, M. P. et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142, 699–713 (2010).
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
Rosenberg, S. A. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17, 4550–4557 (2011).
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
Espinosa-Carrasco, G. et al. Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors. Cancer Cell 42, 1202–1216.e8 (2024).
Magen, A. et al. Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma. Nat. Med. 29, 1389–1399 (2023).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563–571 (2018).
Zhu, C. et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6, 1245–1252 (2005).
Stillman, B. N. et al. Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J. Immunol. 176, 778–789 (2006).
Toscano, M. A. et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat. Immunol. 8, 825–834 (2007).
Jin, H.-T. et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl Acad. Sci. USA 107, 14733–14738 (2010).
Cagnoni, A. J. et al. Galectin-1 fosters an immunosuppressive microenvironment in colorectal cancer by reprogramming CD8+ regulatory T cells. Proc. Natl Acad. Sci. USA 118, e2102950118 (2021).
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
Le, D. T. et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J. Clin. Oncol. 38, 11–19 (2020).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
Choueiri, T. K. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 384, 829–841 (2021).
Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Cascone, T. et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat. Med. 27, 504–514 (2021).
Borate, U., et al. Phase Ib study of the anti-TIM-3 antibody MBG453 in combination with decitabine in patients with high-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood 134, 570 (2019).
Acharya, N., Sabatos-Peyton, C. & Anderson, A. C. Tim-3 finds its place in the cancer immunotherapy landscape. J. Immunother. Cancer 8, e000911 (2020).
Curigliano, G. et al. Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin. Cancer Res. 27, 3620–3629 (2021).
Kaufman, H. L. et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 17, 1374–1385 (2016).
Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).
Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).
Garnham, R. et al. ST3 beta-galactoside alpha-23-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Commun. Biol. 7, 276 (2024).
Duxfield, A. et al. The androgen receptor and MYC synergise to modulate the synthesis of Siglec-7 ligands in prostate cancer. Preprint at bioRxiv https://doi.org/10.1101/2025.10.15.682547 (2025).
Daley, D. et al. Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat. Med. 23, 556–567 (2017).
Fernandes, R. A. et al. Immune receptor inhibition through enforced phosphatase recruitment. Nature 586, 779–784 (2020).
Lippert, A. H. et al. Antibody agonists trigger immune receptor signaling through local exclusion of receptor-type protein tyrosine phosphatases. Immunity 57, 256–270.e10 (2024).
Juszczynski, P. et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl Acad. Sci. USA 104, 13134–13139 (2007).
Ilarregui, J. M. et al. Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat. Immunol. 10, 981–991 (2009).
Dardalhon, V. et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly−6G+ myeloid cells. J. Immunol. 185, 1383–1392 (2010).
Zhou, Q. et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117, 4501–4510 (2011).
Kouo, T. et al. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol. Res 3, 412–423 (2015).
Tiraboschi, C. et al. Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. J. Immunother. Cancer 8, e001535 (2020).
Sturgill, E. R. et al. Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity. Oncoimmunology 10, 1892265 (2021).
Li, Y. M. et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6, 459–469 (2004).
Veth, T. S. et al. Improvements in glycoproteomics through architecture changes to the Orbitrap Tribrid MS platform. Anal. Chem. 97, 11413–11423 (2025).
Elias, J. E. & Gygi, S. P. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat. Methods 4, 207–214 (2007).
Yamaji, T., Teranishi, T., Alphey, M. S., Crocker, P. R. & Hashimoto, Y. A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues. A comparison with Siglec-9. J. Biol. Chem. 277, 6324–6332 (2002).
Attrill, H. et al. Siglec-7 undergoes a major conformational change when complexed with the α(2,8)-disialylganglioside GT1b. J. Biol. Chem. 281, 32774–32783 (2006).
Gasteiger, E. et al. ExPASy: the proteomics server for in-depth protein knowledge and analysis. Nucleic Acids Res. 31, 3784–3788 (2003).
Wang, Y. et al. Specificity of mouse and human Fcgamma receptors and their polymorphic variants for IgG subclasses of different species. Eur. J. Immunol. 52, 753–759 (2022).
Derer, S. et al. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. MAbs 6, 409–421 (2014).
Lohse, S. et al. An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo. Cancer Res. 76, 403–417 (2016).
HaileMariam, M. et al. S-Trap, an ultrafast sample-preparation approach for shotgun proteomics. J. Proteome Res. 17, 2917–2924 (2018).
Zecha, J. et al. TMT labeling for the masses: a robust and cost-efficient, in-solution labeling approach. Mol. Cell. Proteom. 18, 1468–1478 (2019).
Brenes, A., Hukelmann, J., Bensaddek, D. & Lamond, A. I. Multibatch TMT reveals false positives, batch effects and missing values. Mol. Cell. Proteom. 18, 1967–1980 (2019).
Hebert, A. S. et al. Improved precursor characterization for data-dependent mass spectrometry. Anal. Chem. 90, 2333–2340 (2018).
Zhou, H. et al. Robust phosphoproteome enrichment using monodisperse microsphere-based immobilized titanium (IV) ion affinity chromatography. Nat. Protoc. 8, 461–480 (2013).
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res. 10, 1794–1805 (2011).
Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat. Protoc. 11, 2301–2319 (2016).
UniProt Consortium UniProt: a worldwide hub of protein knowledge. Nucleic Acids Res. 47, D506–D515 (2019).
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 47, W191–W198 (2019).
Morpheus (The Broad Institute); https://software.broadinstitute.org/morpheus
Kulkarni, R. U., Wang, C. L. & Bertozzi, C. R. Analyzing nested experimental designs: a user-friendly resampling method to determine experimental significance. PLoS Comput. Biol. 18, e1010061 (2022).
Perez-Riverol, Y. et al. The PRIDE database at 20 years: 2025 update. Nucleic Acids Res. 53, D543–D553 (2025).
Leus, N. G. J. et al. HDAC1-3 inhibitor MS-275 enhances IL10 expression in RAW264.7 macrophages and reduces cigarette smoke-induced airway inflammation in mice. Sci. Rep. 7, 45047 (2017).
Bhat, M. F. et al. Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections. Drug Discov. Today 29, 104193 (2024).
Leus, N. G. J. et al. HDAC 3-selective inhibitor RGFP966 demonstrates anti-inflammatory properties in RAW 264.7 macrophages and mouse precision-cut lung slices by attenuating NF-κB p65 transcriptional activity. Biochem. Pharmacol. 108, 58–74 (2016).
Li, X. et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene 40, 1836–1850 (2021).
Guerriero, J. L. et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543, 428–432 (2017).
Hamaidia, M. et al. Inhibition of EZH2 methyltransferase decreases immunoediting of mesothelioma cells by autologous macrophages through a PD-1-dependent mechanism. JCI Insight 4, e128474 (2019).
Li, C. et al. EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment. Front. Immunol. 13, 857808 (2022).
Zambuzi, F. A. et al. Decitabine promotes modulation in phenotype and function of monocytes and macrophages that drive immune response regulation. Cells 10, 868 (2021).
Willemsen, L. et al. DOT1L regulates lipid biosynthesis and inflammatory responses in macrophages and promotes atherosclerotic plaque stability. Cell Rep. 41, 111703 (2022).
Zhang, Y. et al. Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS–STING pathway. Commun. Biol. 7, 587 (2024).
De Vries, L. C. S. et al. A JAK1 selective kinase inhibitor and tofacitinib affect macrophage activation and function. Inflamm. Bowel Dis. 25, 647–660 (2019).
Huarte, E. et al. Ruxolitinib, a JAK1/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome. Front. Pharmacol. 12, 650295 (2021).
Akcora, B. Ö et al. TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo. FASEB J. 33, 9466–9475 (2019).
Mathew, D. et al. Combined JAK inhibition and PD-1 immunotherapy for non-small cell lung cancer patients. Science 384, eadf1329 (2024).
Soleimani, M. et al. Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB- and TFE3-mediated lysosome biogenesis and autophagy. Mol. Cancer Ther. 21, 1547–1560 (2022).
Chen, H., Liu, N. & Zhuang, S. Macrophages in renal injury, repair, fibrosis following acute kidney injury and targeted therapy. Front. Immunol. 13, 934299 (2022).
Wang, L. et al. PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. Cell Rep. 41, 111462 (2022).
Qian, J.-F. et al. Isoproterenol induces MD2 activation by β-AR-cAMP-PKA-ROS signalling axis in cardiomyocytes and macrophages drives inflammatory heart failure. Acta Pharmacol. Sin. 45, 531–544 (2024).
Busch, L. et al. Lenalidomide enhances MOR202-dependent macrophage-mediated effector functions via the vitamin D pathway. Leukemia 32, 2445–2458 (2018).
Bogdan, C. & Ding, A. Taxol, a microtubule-stabilizing antineoplastic agent, induces expression of tumor necrosis factor alpha and interleukin-1 in macrophages. J. Leukoc. Biol. 52, 119–121 (1992).
Martinet, W. et al. Everolimus triggers cytokine release by macrophages: rationale for stents eluting everolimus and a glucocorticoid: rationale for stents eluting everolimus and a glucocorticoid. Arterioscler. Thromb. Vasc. Biol. 32, 1228–1235 (2012).
Zhou, Q. et al. Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO Mol. Med. 14, e14502 (2022).
Fang, F. et al. C646 modulates inflammatory response and antibacterial activity of macrophage. Int. Immunopharmacol. 74, 105736 (2019).
Uramatsu, T. et al. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine. Biol. Pharm. Bull. 36, 1271–1277 (2013).
Morsali, D. et al. Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis. Brain 136, 1067–1082 (2013).
Wilson, A. K., Takai, A., Ruegg, J. C. & de Lanerolle, P. Okadaic acid, a phosphatase inhibitor, decreases macrophage motility. Am. J. Physiol. 260, L105–L112 (1991).
Schmidt, N. & Gans, E. H. Tretinoin: a review of its anti-inflammatory properties in the treatment of acne. J. Clin. Aesthet. Dermatol. 4, 22–29 (2011).
Cui, S.-N. et al. Trichostatin A modulates the macrophage phenotype by enhancing autophagy to reduce inflammation during polymicrobial sepsis. Int. Immunopharmacol. 77, 105973 (2019).
Tseng, W.-C., Tsai, M.-T., Chen, N.-J. & Tarng, D.-C. Trichostatin A alleviates renal interstitial fibrosis through modulation of the M2 macrophage subpopulation. Int. J. Mol. Sci. 21, 5966 (2020).
Han, H., Kang, J.-K., Ahn, K. J. & Hyun, C.-G. DMSO alleviates LPS-induced inflammatory responses in RAW264.7 macrophages by inhibiting NF-κB and MAPK activation. BioChem (Basel) 3, 91–101 (2023).
Lee, S. J., Lee, S. H., Koh, A. & Kim, K. W. EGF-conditioned M1 macrophages Convey reduced inflammation into corneal endothelial cells through exosomes. Heliyon 10, e26800 (2024).
Shabani, M. et al. Resveratrol alleviates obesity-induced skeletal muscle inflammation via decreasing M1 macrophage polarization and increasing the regulatory T cell population. Sci. Rep. 10, 3791 (2020).
O’Neil, J. D. et al. Dexamethasone impairs the expression of antimicrobial mediators in lipopolysaccharide-activated primary macrophages by inhibiting both expression and function of interferon β. Front. Immunol. 14, 1190261 (2023).
Yoshino, T. et al. Immunosuppressive effects of tacrolimus on macrophages ameliorate experimental colitis. Inflamm. Bowel Dis. 16, 2022–2033 (2010).
Joshi, H. et al. The pharmacological implications of flavopiridol: an updated overview. Molecules 28, 7530 (2023).
Iqbal, N. & Iqbal, N. Imatinib: a breakthrough of targeted therapy in cancer. Chemother. Res. Pract. 2014, 357027 (2014).
Tousif, S. et al. Ponatinib drives cardiotoxicity by S100A8/A9-NLRP3-IL-1β mediated inflammation. Circ. Res. 132, 267–289 (2023).
Brownlow, N., Mol, C., Hayford, C., Ghaem-Maghami, S. & Dibb, N. J. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 23, 590–594 (2009).
Murphy, D. A. et al. Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. Future Oncol. 16, 1199–1210 (2020).
Tariq, M. et al. Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer. Biomed. Pharmacother. 161, 114527 (2023).
Blay, J.-Y. & von Mehren, M. Nilotinib: a novel, selective tyrosine kinase inhibitor. Semin. Oncol. 38, S3–S9 (2011).
Du, S.-L., Yuan, X., Zhan, S., Tang, L.-J. & Tong, C.-Y. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock. Biochem. Biophys. Res. Commun. 458, 667–673 (2015).
Hage, C. et al. Sorafenib induces pyroptosis in macrophages and triggers natural killer cell-mediated cytotoxicity against hepatocellular carcinoma. Hepatology 70, 1280–1297 (2019).
De, M. et al. MEK1/2 inhibition decreases pro-inflammatory responses in macrophages from people with cystic fibrosis and mitigates severity of illness in experimental murine methicillin-resistant Staphylococcus aureus infection. Front. Cell. Infect. Microbiol. 14, 1275940 (2024).
Fu, W. et al. Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells. Elife 3, e04631 (2014).
Hong, H. & Benveniste, E. N. The immune regulatory role of protein kinase CK2 and its implications for treatment of cancer. Biomedicines 9, 1932 (2021).
Leitch, A. E., Haslett, C. & Rossi, A. G. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br. J. Pharmacol. 158, 1004–1016 (2009).
Sun, M. et al. Vemurafenib inhibits necroptosis in normal and pathological conditions as a RIPK1 antagonist. Cell Death Dis. 14, 555 (2023).
Doran, A. C. et al. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis. J. Clin. Invest. 127, 4075–4089 (2017).
Al Kindi, H. et al. Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction. J. Thorac. Cardiovasc. Surg. 148, 2316–2323 (2014).
Tariq, M. et al. Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway. Acta Pharmacol. Sin. 38, 1501–1511 (2017).
Wolf, A. M. et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc. Natl Acad. Sci. USA 102, 13622–13627 (2005).
Sellon, D. C., Walker, K. M., Russell, K. E., Perry, S. T. & Fuller, F. J. Phorbol ester stimulation of equine macrophage cultures alters expression of equine infectious anemia virus. Vet. Microbiol. 52, 209–221 (1996).
Hill, A. A. et al. Activation of NF-κB drives the enhanced survival of adipose tissue macrophages in an obesogenic environment. Mol. Metab. 4, 665–677 (2015).
Frankenberg, T., Kirschnek, S., Häcker, H. & Häcker, G. Phagocytosis-induced apoptosis of macrophages is linked to uptake, killing and degradation of bacteria. Eur. J. Immunol. 38, 204–215 (2008).
Matsuda, T. et al. Cabozantinib prevents the progression of metabolic dysfunction-associated steatohepatitis by inhibiting the activation of hepatic stellate cell and macrophage and attenuating angiogenic activity. Heliyon 10, e38647 (2024).
